Mersana Therapeutics, Inc. MRSN
29.08 USD 0.00 (+0.00%)
At closeJan 6, 2026, 4:00 PM EST
29.36 +0.28 +0.96%
After hours · Jan 6, 4:00 PM ET
28.78 Day range 29.08
52-week range unavailable
- YTD
- +0.52%
- 1 year
- -14.47%
- Market cap
- 189.01M
- Revenue (ttm)
- 34.84M
- Profit margin
- -214.20%
- Shares out
- 123.53M
- Forward P/E
- -2.19
- YTD return
- +0.52%
- 1-year return
- -14.47%
- Volume
- 624.02K
- Open
- 28.78
- Previous close
- 29.08
- Day's range
- 28.78 – 29.08
- Analysts
- Strong Buy
- Price target
- 6.50 (-77.6%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 5.43
- Price / book
- 5.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 63.70%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 9.30%
- 50-day average
- 2.16
- 200-day average
- 2.47
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 6.50 -77.6% downside
Now 29.08
- Target (low)
- 3.00
- Target (mean)
- 6.50
- Target (high)
- 9.00
Ratings (0m) 10 8 buy · 2 hold · 0 sell
- Strong buy0
- Buy8
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16455.
Financials — quick view
MRSN Revenue — quarterly 11.01M
MRSN Net income — quarterly -7.54M
MRSN EPS — quarterly -1.51
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.18 | -0.09 | +0.09 | +50.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.18 | -0.20 | -0.02 | -11.11% |
| May 9, 2024 | Mar 1, 2024 | -0.18 | -0.16 | +0.02 | +11.11% |
| Feb 28, 2024 | Dec 1, 2023 | -0.20 | -0.16 | +0.04 | +20.00% |
| Nov 7, 2023 | Sep 1, 2023 | -0.31 | -0.35 | -0.04 | -12.90% |
| Aug 8, 2023 | Jun 1, 2023 | -0.39 | -0.47 | -0.08 | -20.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2024 | Citigroup | main | Buy | Buy |
| Aug 14, 2024 | Baird | main | Neutral | Neutral |
| Mar 19, 2024 | JP Morgan | up | Underweight | Neutral |
| Feb 29, 2024 | Wedbush | up | Neutral | Outperform |
| Feb 29, 2024 | Truist Securities | up | Hold | Buy |
| Feb 29, 2024 | Baird | main | Neutral | Neutral |
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mersana.com
News
Cwm LLC Cuts Stock Holdings in Mersana Therapeutics, Inc. $MRSN 
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN) 
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders 
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN 
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights 
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights 
HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN 
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN 
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
Your note
Sign in to keep a note on MRSN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALA MOHAN | Officer | Sale | Oct 27, 2024 | 54,731 |
| CARVAJAL ALEJANDRA V. | Officer | Sale | Oct 2, 2024 | 63,716 |
| DERE WILLARD H | Director | Stock Award(Grant) | Jan 1, 2024 | 39,182 |
| DESCHUYTNER BRIAN | Chief Operating Officer | Sale | Oct 2, 2024 | 94,824 |
| HUBER MARTIN H JR | Chief Executive Officer | Sale | Sep 11, 2024 | 116,327 |
| LOWINGER TIMOTHY B | Chief Technology Officer | Sale | Oct 2, 2024 | 235,642 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 15.68% | 19,364,688 | 29.63M | Sep 29, 2024 |
| Nextech Invest Ag | 9.77% | 12,067,246 | 18.46M | Sep 29, 2024 |
| VR Adviser, LLC | 9.17% | 11,328,000 | 17.33M | Sep 29, 2024 |
| Bain Capital Life Sciences Investors, LLC | 7.01% | 8,663,673 | 13.26M | Sep 29, 2024 |
| Blackrock Inc. | 6.98% | 8,621,861 | 13.19M | Sep 29, 2024 |
| Vanguard Group Inc | 5.81% | 7,177,458 | 10.98M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.81% | 3,470,892 | 5.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.40% | 2,966,700 | 4.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.23% | 1,524,973 | 2.33M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.96% | 1,179,839 | 1.81M | Aug 30, 2024 |
| Vanguard Explorer Fund, Inc. | 0.50% | 614,971 | 940.90K | Jul 30, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 538,996 | 824.66K | Oct 30, 2024 |